Literature DB >> 15080299

Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.

Pei Lin1, Rebecca Owens, Guido Tricot, Carla S Wilson.   

Abstract

Bone marrow aspirates from 306 patients with multiple myeloma were analyzed by flow cytometric immunophenotyping. The plasma cells (PCs) were identified by their characteristic light scatter distribution and reactivity patterns to CD138, CD38, and CD45. Monoclonality was confirmed by immunoglobulin light chain analysis. The immunophenotypic profile of the PCs was determined with a panel of antibodies. Moderate to bright expression of CD56, CD117, CD20, CD45, and CD52 was detected in 71.7%, 17.8%, 9.3%, 8.8%, and 5.2% of cases, respectively. These antigens were expressed by a distinct subpopulation of the PCs in 6.3%, 2.2%, 3.7%, 2.9%, and 2.6% of additional cases. CD19 was negative in more than 99% of cases. The combination of CD38 and CD138 was superior to CD38 alone for identifying CD45+ myeloma and separating CD20+ myeloma from B-cell lymphoma. PC immunophenotyping might be useful for detecting minimal residual disease in cases with aberrant antigen expression and for selection of therapeutic agents that have specific membrane targets.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15080299     DOI: 10.1309/74R4-TB90-BUWH-27JX

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  134 in total

Review 1.  Immunotherapy strategies for multiple myeloma: the present and the future.

Authors:  Frederick L Locke; Taiga Nishihori; Melissa Alsina; Mohamed A Kharfan-Dabaja
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

2.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

Review 3.  Nanotherapeutics for multiple myeloma.

Authors:  Alexander Zheleznyak; Monica Shokeen; Samuel Achilefu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

4.  Synthesis and Evaluation of Thiazoloquinolinones with Linkers To Enable Targeting of CD38.

Authors:  Stephen S Scully; Zachary J Minden; Ratul Mukerji; Elizaveta Andrianova; James Kaberna; Scott Lentini; Carlos Tassa; Zhaolin Wang; Susan Low; Kevin A McDonnell
Journal:  ACS Med Chem Lett       Date:  2016-12-22       Impact factor: 4.345

Review 5.  Daratumumab for the treatment of AL amyloidosis.

Authors:  M Hasib Sidiqi; Morie A Gertz
Journal:  Leuk Lymphoma       Date:  2018-07-22

Review 6.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

7.  Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.

Authors:  Tae-Dong Jeong; Chan-Jeoung Park; Hyoeun Shim; Seongsoo Jang; Hyun-Sook Chi; Dok Hyun Yoon; Dae-Young Kim; Jung-Hee Lee; Je-Hwan Lee; Cheolwon Suh; Kyoo Hyung Lee
Journal:  Korean J Hematol       Date:  2012-12-24

8.  Fatal cerebral hemorrhage in a patient with CD19-positive IgM-producing aggressive plasma cell myeloma, hyperviscosity syndrome and cryoglobulinemia.

Authors:  Adnan Alatoom; Rania Elsabrouty; Jason Willis; Christie Boils; Ravindra Sarode; Ibrahim Hashim; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2009-02-09

9.  Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.

Authors:  Jayeeta Ghose; Domenico Viola; Cesar Terrazas; Enrico Caserta; Estelle Troadec; Jihane Khalife; Emine Gulsen Gunes; James Sanchez; Tinisha McDonald; Guido Marcucci; Balveen Kaur; Michael Rosenzweig; Jonathan Keats; Steven Rosen; Amrita Krishnan; Abhay R Satoskar; Craig C Hofmeister; Flavia Pichiorri
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

10.  Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.

Authors:  Prashant R Tembhare; Constance M Yuan; David Venzon; Raul Braylan; Neha Korde; Elisabet Manasanch; Diamond Zuchlinsky; Katherine Calvo; Roger Kurlander; Manisha Bhutani; Nishant Tageja; Irina Maric; Marcia Mulquin; Mark Roschewski; Mary Kwok; David Liewehr; Ola Landgren; Maryalice Stetler-Stevenson
Journal:  Leuk Res       Date:  2013-12-11       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.